Colonoscopy

Redefining Colorectal Cancer (CRC) Landscape Report with DLI's Epidemiology Study, Drug Insights, Price Reimbursement, and Regulatory Consulting Services | Disease Landscape Insights

Retrieved on: 
Monday, October 9, 2023

The diagnostic landscape of this disease is diverse wherein colonoscopy recommendations are given by doctors due to its accuracy.

Key Points: 
  • The diagnostic landscape of this disease is diverse wherein colonoscopy recommendations are given by doctors due to its accuracy.
  • Apart from that ct scan colon cancer and ct scan for bowel cancer, may also be suggested for the detection of colorectal malignant neoplasm.
  • It has been assisting them with regulatory consulting, pharma consulting services, post launch strategies, product pipeline assessment, and treatment gaps identification.
  • Find out more about Tonsillitis symptoms, consulting services, drug costs, FDA-approved medications, disease landscape, regulatory insights, epidemiology, and price reimbursement.

Redefining Colorectal Cancer (CRC) Landscape Report with DLI's Epidemiology Study, Drug Insights, Price Reimbursement, and Regulatory Consulting Services | Disease Landscape Insights

Retrieved on: 
Monday, October 9, 2023

The diagnostic landscape of this disease is diverse wherein colonoscopy recommendations are given by doctors due to its accuracy.

Key Points: 
  • The diagnostic landscape of this disease is diverse wherein colonoscopy recommendations are given by doctors due to its accuracy.
  • Apart from that ct scan colon cancer and ct scan for bowel cancer, may also be suggested for the detection of colorectal malignant neoplasm.
  • It has been assisting them with regulatory consulting, pharma consulting services, post launch strategies, product pipeline assessment, and treatment gaps identification.
  • Find out more about Tonsillitis symptoms, consulting services, drug costs, FDA-approved medications, disease landscape, regulatory insights, epidemiology, and price reimbursement.

Oracle Brings Generative AI Capabilities to Healthcare

Retrieved on: 
Monday, September 18, 2023

LAS VEGAS, Sept. 18, 2023 /PRNewswire/ -- Oracle Health Conference -- Oracle today announced new generative AI services for healthcare organizations. Integrated with Oracle's electronic health record (EHR) solutions, the new Oracle Clinical Digital Assistant enables providers to leverage the power of generative AI together with voice commands to reduce manual work so they can focus more attention on patient care. It also makes it easy for patients to take self-service actions such as scheduling appointments or checking clinical information at their convenience using simple voice commands.

Key Points: 
  • New capabilities combine the power of generative AI and voice to help providers focus more on patient engagement, building trust, and improving care
    Patients will now have the freedom to get quick answers to clinical questions, schedule appointments, and more via simple voice commands
    LAS VEGAS, Sept. 18, 2023 /PRNewswire/ -- Oracle Health Conference -- Oracle today announced new generative AI services for healthcare organizations.
  • Integrated with Oracle's electronic health record (EHR) solutions, the new Oracle Clinical Digital Assistant enables providers to leverage the power of generative AI together with voice commands to reduce manual work so they can focus more attention on patient care.
  • The generative AI-powered Oracle Clinical Digital Assistant alleviates this issue to enable physicians to give their full attention to patients while dramatically simplifying administrative tasks.
  • New capabilities in the Oracle Digital Assistant Platform also enable patients to take more control over their healthcare.

Costs for Common Health Care Procedures Significantly Higher When Performed in Hospital Outpatient Departments

Retrieved on: 
Thursday, September 14, 2023

WASHINGTON, Sept. 14, 2023 /PRNewswire/ -- When common medical procedures were performed in a hospital outpatient department (HOPD) rather than a doctor's office, costs were substantially higher according to a national analysis of tens of millions of claims. The analysis, released by the Blue Cross Blue Shield Association (BCBSA), shows the costs for prevalent procedures like mammograms or colonoscopies were consistently higher — as much as 58% more expensive — when performed in HOPD settings. These higher hospital prices mean higher costs to consumers.

Key Points: 
  • These higher hospital prices mean higher costs to consumers.
  • To examine the cost disparities at different health care locations, Blue Health Intelligence® analyzed deidentified claims data for six common, everyday outpatient procedures, covering 133 million Blue Cross and Blue Shield members from 2017 through 2022.
  • Price differences in 2022 for common procedures based on setting were:
    Mammograms cost 32% more in an HOPD than in a doctor's office.
  • These commonsense solutions address the root causes of rising health care costs and prioritize the needs of patients," continued Merritt.

EQS-News: Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advance

Retrieved on: 
Saturday, September 16, 2023

Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advance

Key Points: 
  • Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advance
    The issuer is solely responsible for the content of this announcement.
  • Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%
    BERKELEY, US – MAINZ, Germany – September 13, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today positive topline results from its ColoFuture study.
  • The results of this groundbreaking study included sensitivity for colorectal cancer of 94% with a specificity of 97% and a sensitivity for advanced adenoma of 81%.
  • COLOFUTURE is an international clinical study evaluating the performance of the Mainz Biomed Colorectal Cancer Screening Test.

Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%

Retrieved on: 
Wednesday, September 13, 2023

BERKELEY, Calif. and MAINZ, Germany, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today positive topline results from its ColoFuture study. The ColoFuture study is a multi-center international clinical trial assessing the potential to integrate a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert®, the Company’s highly efficacious, and easy-to-use screening test for colorectal cancer (CRC) which is being commercialized across Europe and in select international territories. The results of this groundbreaking study included sensitivity for colorectal cancer of 94% with a specificity of 97% and a sensitivity for advanced adenoma of 81%.

Key Points: 
  • The results of this groundbreaking study included sensitivity for colorectal cancer of 94% with a specificity of 97% and a sensitivity for advanced adenoma of 81%.
  • COLOFUTURE is an international clinical study evaluating the performance of the Mainz Biomed Colorectal Cancer Screening Test.
  • The primary endpoints of the study are to determine sensitivity and specificity for colorectal adenocarcinoma.
  • There are multiple secondary and exploratory endpoints including determining sensitivity and specificity for advanced precancerous lesions in the colon.

Mainz Biomed Announces Live Launch of ColoAlert® with testDNA Laboratory in Poland

Retrieved on: 
Tuesday, August 22, 2023

BERKELEY, Calif. and MAINZ, Germany, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces the commercial launch of ColoAlert® in Poland, made possible through a strategic collaboration with testDNA Sp.

Key Points: 
  • BERKELEY, Calif. and MAINZ, Germany, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces the commercial launch of ColoAlert® in Poland, made possible through a strategic collaboration with testDNA Sp.
  • The partnership marks another significant step forward in providing new and innovative testing options to underserved populations in the battle against colorectal cancer (“CRC”).
  • As an accredited research laboratory sanctioned by the Polish Center for Accreditation, the laboratory is headquartered in Katowice, Poland, and boasts an expansive network of over 300 collection points throughout the country.
  • Together, we are well positioned to help transform and improve the current cancer screening options in Poland and provide timely interventions that have the potential to save lives."

EQS-News: Mainz Biomed Announces Live Launch of ColoAlert® with testDNA Laboratory in Poland

Retrieved on: 
Tuesday, August 22, 2023

The partnership marks another significant step forward in providing new and innovative testing options to underserved populations in the battle against colorectal cancer (“CRC”).

Key Points: 
  • The partnership marks another significant step forward in providing new and innovative testing options to underserved populations in the battle against colorectal cancer (“CRC”).
  • As an accredited research laboratory sanctioned by the Polish Center for Accreditation, the laboratory is headquartered in Katowice, Poland, and boasts an expansive network of over 300 collection points throughout the country.
  • With a comprehensive portfolio, testDNA is renowned for delivering state-of-the-art genetic-based testing solutions tailored to individual needs.
  • Together, we are well positioned to help transform and improve the current cancer screening options in Poland and provide timely interventions that have the potential to save lives."

Kips Bay Endoscopy Center Now Incorporates Artificial Intelligence System for Enhanced Colonoscopy Screenings in New York City

Retrieved on: 
Thursday, August 17, 2023

Kips Bay Endoscopy Center (KBEC), a Covenant Physician Partner , will offer patients receiving a colonoscopy an enhanced screening with the aid of GI Genius™ intelligent endoscopy module.

Key Points: 
  • Kips Bay Endoscopy Center (KBEC), a Covenant Physician Partner , will offer patients receiving a colonoscopy an enhanced screening with the aid of GI Genius™ intelligent endoscopy module.
  • The GI Genius™ module employs artificial intelligence (AI) to help physicians detect polyps—a powerful new ally in the fight against colorectal cancer.
  • “We are the only privately-owned and fully independent surgery center offering artificial intelligence assisted colonoscopies in Midtown Manhattan,” added Ms. Yuen.
  • New artificial intelligence system: first validation study versus experienced endoscopists for colorectal polyp detection.

Motus GI Receives Approval from the Israeli Ministry of Health to Initiate Commercial Sales of its Pure-Vu® EVS System

Retrieved on: 
Thursday, August 10, 2023

“We are pleased to secure regulatory clearance for the Pure-Vu EVS System in Israel, which is considered an advanced medical system globally and one of the largest markets in this region.

Key Points: 
  • “We are pleased to secure regulatory clearance for the Pure-Vu EVS System in Israel, which is considered an advanced medical system globally and one of the largest markets in this region.
  • Leading healthcare systems in a number of regions in the U.S. and the Veterans Health Administration (VHA) are currently utilizing the Pure-Vu EVS System.
  • The Pure-Vu System EVS integrates with standard and slim colonoscopes, to improve visualization during colonoscopy while preserving established procedural workflow and techniques.
  • The Pure-Vu EVS is already cleared by the U.S. Food and Drug Administration (FDA) to help facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy.